The U.S. Food and Drug Administration today approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease.
Read more: FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes